328 related articles for article (PubMed ID: 10168752)
1. The role of economic evaluation in the pricing and reimbursement of medicines.
Drummond M; Jönsson B; Rutten F
Health Policy; 1997 Jun; 40(3):199-215. PubMed ID: 10168752
[TBL] [Abstract][Full Text] [Related]
2. Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?
Oliva-Moreno J; Puig-Junoy J; Trapero-Bertran M; Epstein D; Pinyol C; Sacristán JA
Value Health; 2020 Jan; 23(1):25-31. PubMed ID: 31952669
[TBL] [Abstract][Full Text] [Related]
3. The pricing of pharmaceuticals: an international comparison.
Dickson M
Clin Ther; 1992; 14(4):604-10; discussion 603. PubMed ID: 1525794
[TBL] [Abstract][Full Text] [Related]
4. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
5. Methods for the comparative evaluation of pharmaceuticals.
Zentner A; Velasco-Garrido M; Busse R
GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
[TBL] [Abstract][Full Text] [Related]
6. Integration of economic appraisal and health care policy in a health insurance system; the Dutch case.
Rutten F; van der Linden JW
Soc Sci Med; 1994 Jun; 38(12):1609-14. PubMed ID: 8047918
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation and health care decision-making.
Rutten F
Health Policy; 1996 Jun; 36(3):215-29. PubMed ID: 10158267
[TBL] [Abstract][Full Text] [Related]
8. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
[TBL] [Abstract][Full Text] [Related]
9. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand.
Danzon PM; Ketcham JD
Front Health Policy Res; 2004; 7():1-54. PubMed ID: 15612334
[TBL] [Abstract][Full Text] [Related]
10. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom.
Gross DJ; Ratner J; Perez J; Glavin SL
Health Care Financ Rev; 1994; 15(3):127-40. PubMed ID: 10137794
[TBL] [Abstract][Full Text] [Related]
11. Pricing and reimbursement of orphan drugs: the need for more transparency.
Simoens S
Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
[TBL] [Abstract][Full Text] [Related]
12. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
Vacca C; Acosta A; Rodriguez I
Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
[TBL] [Abstract][Full Text] [Related]
13. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
14. Pricing and reimbursement of drugs in Ireland.
Barry M; Tilson L; Ryan M
Eur J Health Econ; 2004 Jun; 5(2):190-4. PubMed ID: 15452757
[TBL] [Abstract][Full Text] [Related]
15. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
16. A comparison of pharmaceutical reimbursement agencies' processes and methods in France and Scotland.
Bending M; Hutton J; McGrath C
Int J Technol Assess Health Care; 2012 Apr; 28(2):187-94. PubMed ID: 22559763
[TBL] [Abstract][Full Text] [Related]
17. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of health care and policymaking.
Johannesson M
Health Policy; 1995 Sep; 33(3):179-90. PubMed ID: 10145120
[TBL] [Abstract][Full Text] [Related]
19. Government regulation of pricing and reimbursement of prescription medicines: results of a recent multi-country review.
Kingham R; Wheeler J
Food Drug Law J; 2009; 64(1):101-14. PubMed ID: 19998574
[TBL] [Abstract][Full Text] [Related]
20. Can economic evaluation guidelines improve efficiency in resource allocation? The cases of Portugal, The Netherlands, Finland, and the United Kingdom.
Kanavos P; Trueman P; Bosilevac A
Int J Technol Assess Health Care; 2000; 16(4):1179-92. PubMed ID: 11155837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
